In the field of photodynamic therapy, there is a constant search for more efficient and specific photosensitisers. The phthalocyanines are a group of compounds which has excited interest as potentially useful photosensitisers and been much investigated over recent years (reviewed by Rosenthal, 1991) . There is however, still scope for increasing the specificity of phthalocyanines for tumour tissue. Liposome incorporation is one useful possibility (Reddi et al., 1987) , and targeting with antibodies another. It has been previously shown that liposome encapsulated sulphonated aluminium phthalocyanine (AlSPc), is highly phototoxic when targeted to cells by antibody and activated by light (Morgan et al., 1989) . The phototoxicity of cells is probably due to a Type II photooxidation mechanism in which singlet oxygen is produced by energy transfer from light activated AlSPc to molecular oxygen (Sonoda et al., 1987; Agarwal et al., 1990) . However, a contribution to cytotoxicity from a Type I mechanism cannot be ruled out (Kimel et al., 1989; Ferraudi et al., 1988) . The singlet oxygen mechanism is most likely favoured over a Type I mechanism in this study because the AlSPc is in solution inside the liposome, not bound to a target substrate; and under the conditions of treatment there is no oxygen deprivation. Antibody specificity of the AlSPc liposomes was shown on single cell populations, with non specific antibodies and cell lines not expressing appropriate antigen acting as negative controls. The use of such liposomes as an in vivo therapy may not be effective because of their uptake in the reticuloendothelial system and limited access to target cells outside the vasculature. Therefore, it was postulated (Morgan et al., 1989 ) that antibody targeted photosensitive liposomes might be a suitable agent for ex vivo use such as in the purging of residual tumour from bone marrow for autologous transplantation, and also for treatment for accessible diseases in anatomical compartments such as bladder carcinoma or tumours in the serous cavities. The present paper demonstrates the feasibility of targeting and destroying subpopulations of T-lymphocytes and B-cells (using an immortalised B-cell line as a model) in bone marrow with photosensitive liposomes without affecting normal bone marrow cells. (Azim, 1988) . DW-BCL cells were seeded at 1 x 105 cells per ml and cultured in RPMI 1640 medium supplemented with 10% foetal calf serum.
Materials and methods

Cells DW-BCL is an in vitro Epstein Barr virus (EBV) immortalised polyclonal B-cell line
Bone marrow was harvested from normal donors, or patients with non-Hodgkin's lymphoma in remission undergoing harvest for autologous bone marrow transplantation. Peripheral blood was collected from normal donors. The mononuclear cells of bone marrow (BM-cells), or peripheral blood (PBM) were obtained by layering the samples over Lymphoprep (Nycomed, Norway) , centrifuging, and then collecting and washing the cells at the interface. In some experiments, the BM-cells were x-irradiated (3000 rad) to prevent cell division. T-lymphocytes were purified from PBM by incubating in 20% FCS, in a plastic petri-dish at 37°C for 4 h to allow monocytes to adhere. Non adherent cells were removed and were found to be greater than 95% positive for the CD3 antigen (a marker of T-lymphocytes) using UCHTI antibody and flow cytometry. Antibodies 8A is an anti-B-cell mouse monoclonal antibody (subclass, IgGI), directed to an antigen expressed on B-cells from the pre-B stage of ontogeny through to plasma cells (Tazzari et al., 1987 Photosensitisers (i) Tetra-sulphonated AlSPc (tetra-AISPc), prepared by the condensation method (Weber & Busch, 1965) , was a gift from Russell Svenson, Royal Institution, London, UK.
(ii) TLC-AISPc was a preparation made by the thin layer chromatographic separation of a mixture of tetra-, tri-, di-an mono-sulphonated AlSPc (a gift from Ciba-Geigy, Basel, Switzerland), as described in Morgan et al. (1989) . The TLC preparation was enriched for the more hydrophilic tetra-and tri-sulphonated derivatives, with residual amounts of the more lipophilic di-and mono-sulphonated derivatives. HPLC traces run according to the method of Ambroz et al. (1991) (Figure 1 ), show the relative amounts of each component.
Liposomes
Liposomes were small unilamellar vesicles (SUV) with an average diameter of 50 nm, prepared by ultrasonication. They were coupled to SaM antibody with N-hydroxysuccinimidyl 3-(2-pyridyldithio)propionate (SPDP), (Sigma) in the presence of a buffer containing Hepes (10mM) and NaCl (145 mM) by the method of Barbet et al. (1981) . Lipids used were La-dipalmitoyl phosphatidylcholine (DPPC) and cholesterol (both from Sigma), and Lcx-dipalmitoyl phosphatidylethanolamine-pyridyldithiopropionate in the ratio 66:33:1. The latter was derived from La-dipalmitoyl phosphatidylethanolamine (DPPE), (Calbiochem), using SPDP by the method of Barbet et al. (1981) .
For each liposome preparation, 2 x 10-5 moles of SaM containing a trace of '251I-labelled SaM were used for coupling to 4 x 10-' moles of total phospholipid. The radioactive (Stewart, 1980) was 3.4 ± 0.18 x 10-3M (mean ± s.e.m. of seven preparations). The liposomes contained on average 47 molecules of tetra-AlSPc or 49 molecules of TLC-AlSPc. The liposomes were very stable to storage at 4°C in the dark; and over a period of 1 month leaked 5-6% of the contents. They were also stable under the cell treatment conditions, with no detectable AlSPc leakage after treatment with 7.2 J cm2 of light. The liposomes were not washed before use unless they had been stored for prolonged periods.
Red light source The light source consisted of two 15 W Grolux fluorescent tubes (Thorn Lighting Ltd.) fitted with a red gelatin filter, model 182 (Lee filters Ltd.), as described by Chan et al. (1986) , which gave peak emissions between 600 and 700 nm. The mean total light intensity (over all the transmitted wavelengths) was 2 mW cm2 as measured by a Coherent 212 Power meter. Cells were irradiated at 4°C to prevent thermal effects, the maximum increase of temperature being 40C after 1 h illumination. For each experimental point, 1 x 104 cells harvested at the log phase of growth were added to triplicate flat bottomed wells in 96-well culture plates. They were incubated at 4°C with 50,l antibody at 2 tg ml-' for 30 min, and then with 50 jsl liposomes for 30 min, with three washes in cold serum free medium between each step.
Antibodies used were 8A (1/1000 dilution of ascites which contained approximately 2 tg ml-' of 8A) or UCHT1 (irrelevant control), followed by varying liposome dilutions. The liposomes were prepared with 2 mM tetra-AISPc and different liposome dilutions were used to give a series of dose response curves. The lowest dilution of liposomes contained 0.3 nmoles of AlSPc per well (in a total volume of 50 tl) and doubling dilutions of this were made for the remainder, containing respectively 0.15, 0.08, and 0.04 nmoles. The highest AlSPc concentration corresponded to a 6 jamolar dose. Only the highest AlSPc concentration was used with the irrelevant antibody. Controls were incubated with antibody and buffer-only liposomes at similar lipid concentrations as those with AlSPc. Previous studies (unpublished work) have shown that the absolute number of liposomes in quantities similar to those used here, had no significant effect on cell growth; so buffer-only liposomes were only added in the same proportions as AlSPc-containing liposomes.
Before illumination DW-BCL cells were resuspended in a volume of 50 jil of RPMI medium without-phenol red or FCS, and then exposed to red light for between 0 and 30 min to deliver total energies of up to 5.4 J cm-2 as shown in Figure 2 .
Targeting and phototoxicity of T-lymphocytes Isolated Tlymphocytes (2 million per treatment point) were incubated with UCHT1 at 2 fg ml-', and liposomes and exposed to red light in the same way as DW-BCL cells. Only one AlSPc concentration was used, at 0.3 nmoles, and one light dose, of 3.2 J cm-2. Light was given in the absence of phenol red and FCS. The cells were then suspended at 2 million ml-' and T-lymphocytes already present in BM-cells were also targeted using UCHT1 and liposomes, but in this case, only CFU-GM colony recovery was assessed and no attempt was made to determine lymphocyte survival.
Phototoxicity of CFU-GM progenitor cells When the effects of the AlSPc-liposomes on the 'non-targeted' progenitor cells were to be examined the BM-cells were not x-irradiated, and the surviving cells were grown up as CFU-GM colonies. For these experiments the cells at 7.5 x i0' per well plus 10% added DW-BCL cells were incubated with antibody and/or liposomes as shown in Figure 4 , and using similar quantities to previously, then exposed to a total of 0 or 3.6 J cm-2 of light. Again, 2 mM tetra-AlSPc-liposomes were used at 0.3 nmoles of AlSPc per well, for all samples.
Cell growth assays and viability The DW-BCL cell line is immortalised, but not transformed, and does not form colonies in soft agar. A tritiated thymidine incorporation assay was therefore used to assess the phototoxicity of this cell line. Surviving DW-BCL cells were grown after treatment by incubating in a humidified atmosphere with 5% CO2 at 37@C for 72 h to allow time for the death of non-viable cells and the regrowth of cells capable of reproducing. They were pulsed with 3H thymidine (Amersham) at 0.5 IACi well for the last 6 h, then harvested onto filters with an Automash cell harvester (Dynatech). The dried filters were transferred to vials, scintillation fluid was added, and the radioactivity in the samples was counted. In the experiments for examining the effects of photosensitive liposomes on DW-BCL cells in mixtures the BM-cells were xirradiated and radioactive counts from controls containing only x-irradiated BM-cells were subtracted from those containing both DW-BCL cells and BM-cells. For myeloid colony growth, a modification of the method of Pike and Robinson (1970) was used. DW-BCL/BM-cell mixtures or pure BM-cells in the case of T-lymphocyte targeted samples, were added after treatment to soft agar growth medium in 30 mm petri dishes to give a final number of 2 x 105 BM-cell per dish in 1 ml of medium. The agar medium consisted of Iscove's minimum Dulbecco medium (double strength), foetal calf serum and 0.9% agar dissolved in double distilled water, in the ratio 3:2.5:3, and contained 10% 5,637 bladder carcinoma cell line conditioned medium (Fraser et al., 1988) Samples for CCD camera examination were prepared as follows: mixtures of bone marrow and B-cells incubated with antibody and liposomes were made in the same way as for the phototoxicity studies above, and fixed in 1% formaldehyde solution. Cytospin preparations were then made and the slides stored at 4°C in the dark until examination.
Flow cytometry To assess non-specific uptake of liposomes by DW-BCL/BMcell mixtures the fluorescence of stained cells was examined by flow cytometry on a Coulter EPICS flow cytometer set up to detect red fluorescence from AlSPc and blue fluorescence from a second layer conjugate bound to monocyte-specific monoclonal antibody.
Samples of 2 x I05 cells were incubated for 30 min with 50 1sl of liposomes containing 2 mM tetra-AISPc, but with no SaM attached (to prevent non specific binding of antibodies in a subsequent incubation with a mouse monoclonal antibody). To determine whether cells which took up liposomes non-specifically in the first incubation were also monocytes, the cells were incubated with UCHM1 (cell hydridoma culture medium previously titrated to give optimum binding for monocytes in PBM), followed by the fluorescent second layer, Figure 2 shows the phototoxic effect of AlSPc liposomes on the growth of DW-BCL cell as a percentage of controls as measured by 3H thymidine uptake. In the presence of light and a targeting antibody, 3H thymidine uptake by DW-BCL cells is reduced to less than 1% of controls at the highest doses of tetra-AISPc and light, whereas in the absence of targeting antibody, growth was not significantly affected (student's t-test) at any light dose. LD50 light doses for the different quantities of AlSPc added to cells were 0.73, 1.17, 1.26 and 2.33 Jcm2 for 0.3, 0.15, 0.08 and 0.04nmoles of AlSPc respectively. No LDm was obtained for non-specific toxicity because it did not reach such low levels, even at the longest light exposures used. Typical dose-response curves were obtained for dilutions of liposomes, showing decreasing growth inhibition for increasing liposome dilutions. This effect could be overcome completely by increasing the light exposure time for 0.15 nmoles of AlSPc, but not for the lower doses at the light exposures used here.
In the presence of x-irradiated BM-cells no significant difference (student's t-test) was observed between the phototoxic killing of DW-BCL cells regardless of whether the BM-cells were added before or after targeting of the B-cells with antibody and liposomes, Figure 3 . This indicates that the presence of a 10 fold excess of non-target cells does not interfere with binding of antibody or light access to the target cells. In both cases a greater than two log kill was achieved with an LD50 of 0.7 J cm-2. There was no difference between tetra-AISPc and TLC-AISPc (data of latter not shown). Some non-specific toxicity of DW-BCL cells was observed when UCHT1 was used as an irrelevant antibody for both photosensitiser preparations at higher light doses. For tetra-AISPcliposomes the non-specific phototoxicity was only significant at light doses greater than 1.2 J cm2 (0.005<P<0.01), but not large enough to give an LDm value. However, when the TLC-AlSPc-liposomes were used, there was a much greater non-specific toxicity of DW-BCL cells at light doses of 1.2 J cm 2 (P 0.0005) and above with an LD,o of 1.24 J cm2. Non specific toxicity of TLC-AlSPc liposomes were also significantly greater than that of the tetra-AlSPc at 2.4 J cm 2 (0.025 <P < 0.05) and 3.6 J cm2 (0.005 <P < 0.005). Table I shows the phototoxicity of T-lymphocytes over a period of 18 h after targeting and light exposure. Onset of photokilling is very rapid, with 30% of cells non-viable after 1 h, and very few alive after 18 h. Viability was not counted over longer periods of time because the untreated control cells also deteriorated with time. Figure 4 shows the colony growth of bone marrow samples expressed as a percentage of untreated controls, after treatment with two different antibodies (8A and UCHT1) and AlSPc-liposomes in the presence or absence of light. Bone marrow treated with 8A contained 10% added target DW-BCL cells, whereas the normal CD3 positive component of bone marrow was the target for UCHT1. None of these treatments inhibited CFU-GM growth although they were effective against target cells (Figure 3 , and Table I ). There were no significant differences between any of the treatments, and no evidence of dark toxicity by AlSPc-liposomes. The non specific toxicity by AlSPc-liposomes observed for the DW-BCL cells (above) was not reflected in the recovery of bone marrow colonies. Figure 5a shows the digital pattern of fluorescence produced by exciting AlSPc bound to B-cells cells in bone marrow by 8A antibody. There is a background population of faintly stained cells and some brightly fluorescing target cells. The total number of fluorescent cells was greater than the 10% of added DW-BCL because of the presence of some B-lineage cells and some T-lymphocytes (which bind 8A) among the BM-cells, and non-specific binding and uptake. Figure 5b shows AlSPc bound to cells non-specifically in the absence of antibody. The faintly stained background is present with the occasional bright cell (arrowed). The latter are probably due to uptake of liposomes by cells of monocytoid lineage in the BM-cells or the presence of peripheral blood macrophages taken up during aspiration of the bone marrow sample. It was not within the scope of this study to determine the exact populations of cells in BM-cells that bound liposomes via 8A antibody, but a brief study of the cells taking up AlSPc in the absence of antibody was done by flow cytometry.
Of the four DW-BCL/BM-cell mixtures examined, the results gave a range of 4-7% positive for UCHM1, and 6-12% positive for AlSPc above background, which was set at a level to give 1% positive cells for negative controls. Cells which were positive for both UCHM1 and AlSPc, corresponded to those of UCHM1 only, in the range 4-7% positive. Thus the majority of cells exhibiting non-specific uptake of AlSPc expressed a monocytic phenotype. The table shows the effects of antibody-bound tetra-AISPc liposomes on the viability of isolated peripheral blood T-lymphocytes after red light illumination. Liposomes containing 2 mM tetra-AISPc were conjugated to SaM and bound to T-lymphocytes by UCHTI antibody.
Control tetra-AlSPc liposomes were without SaM.
The viability of T-lymphocytes, measured by Trypan Blue exclusion, is expressed as a percentage of the starting number of cells for each point. Each figure is the mean ofthree experiments with duplicate counts at each time point. Standard errors of the mean were less than 10%. (Sharkis et al., 1980) showed that leukaemic relapse could be prevented by treating bone marrow with the cytotoxic agent 4-HC (4-hydroperoxycyclophosphamide). Another study showed a possible benefit to some patients with acute non-lymphoblastic and lymphoblastic leukaemia purged with Asta Z 7557, but there was a wide range of sensitivity to the drug and individual doses were determined by pre-testing with bone marrow aspirates (Gorin et al., 1986) . A further study showed some evidence of improved disease-free survival in patients with acute myeloblastic leukaemia who received AMBT with grafts purged by 4-HC (Rowley et al., 1989) . More recently, Gorin et al. (1990) , made a multi-centre retrospective analysis of ABMT in Europe to investigate the benefits of mafosfamide purged vs non-purged marrow in acute myeloid leukaemia and found a higher leukaemia-free survival and lower probability of relapse with purging. There are, therefore, some indications that purging, even using such non-specific drugs may have a beneficial effect, although no prospective randomised clinical trial has demonstrated such a benefit.
The problem with pharmacological agents is their adverse effect on haemopoietic stem cells as well as tumour stem cells, which may retard both the onset and extent of haematological reconstitution, an undesirable situation for immunologically compromised patients who have undergone ablative regimes as part of their therapy. Ideally, more selective agents would be of benefit, with a greater differential between tumour kill and stem cell toxicity, resulting in better therapeutic index.
Photosensitisers of various types have previously been shown to have differential toxicity between haemopoietic and tumour progenitor cells, including merocyanine 540 (Sieber et al., 1987) which is now being evaluated in phase I clinical trials, Photofrin II (Atzpodien et al., 1987) , and sulphonated aluminium phthalocyanine (Singer et al., 1988) . However, all of these photosensitisers showed considerably toxicity to haemopoietic stem cells.
The present study has shown no phototoxicity of CFU-GM progenitors, combined with high toxicity of targeted cells which suggests that a targeted method is more selective in action against tumour cells, with a better therapeutic index than treatment with free photosensitiser.
Sulphonated aluminium phthalocyanine was chosen for this investigation because it is available in polar forms which are hydrophilic and therefore suitable for encapsulating in liposomes. Tetra-AlSPc liposomes gave low levels of nonspecific toxicity (Figure 3 ) compared to TLC-AlSPc liposomes which also contained small amounts of the less polar, lower sulphonated derivatives (as shown in Figure 1 ). It is likely that there is the same amount of non-specific adherance to cells for both tetra-AlSPc and TLC-AlSPc liposomes. However, the tetra-AlSPc, being more highly sulphonated, and thus more polar than some of the components in TLCAlSPc, is relatively less able to cross the lipid bilayer of the lipsome and pass into the cell membrane, thus producing less toxicity. Greater non specific toxicity was noted in the DW-BCL/BM-cell mixtures than when the DW-BCL cells alone were targeted. This may be due to the presence of AlSPc bound non-specifically to the large excess of BM-cells. Similar LD50 results were obtained for both specific DW-BCL cell toxicity in marrow (0.70 J cm2) and DW-BCL cells alone (0.73 J cm-2) using 0. (675 nm) which is also one of the main emission peaks of the light source, absorbance due to phenol red and FCS amounts to 1.1%, with the phenol red contribution being 0.4%. This is not sufficient to account for the difference in cellular phototoxicity obtained in the presence and absence of these agents. Human plasma (Kanofsky, 1990) , and FCS (Parker & Stanbro, 1984) , have been shown to quench singlet oxygen. The presence of FCS in the medium would therefore be expected to inhibit the action of the singlet oxygen produced, and protect against its toxicity. It is unlikely that the effects of serum were due to any direct interaction with AlSPc, since it is protected from the external medium by the lipid bilayer.
It is interesting that no toxicity occurred to CFU-GM progenitors, despite the presence of low levels of non-specifically bound AlSPc as shown in Figure 5 . This may be due to a lower susceptibility of progenitors to oxidative damage. Seven day CFU-GM colonies which represent a later, more committed progenitor were not counted because the clusters and colonies were too numerous, which indicates that it is not just the earlier progenitors that were protected. This contrasts with another study also using 8A antibody to target cells (Dinota et al., 1990) , but using free radicals produced by the enzyme activity of xanthine oxidase on a substrate in the medium, in which 7 days, but not 14 days CFU-GM were affected, though their results were otherwise similar to ours.
The antibody targeted liposome system as described here for destroying specifically targeted cells in bone marrow bone appears to have many advantages as a bone marrow purging agent. AlSPc is not toxic until it is activated by red light, and then the onset of photodamage is very rapid as indicated by the decrease in viability of T lymphocytes in Table I . Large quantities of photosensitiser may be encapsulated in the liposomes and an additional amplification occurs during irradiation because each photosensitiser molecule is 'reusable' and can be activated several times over, producing large amounts of the toxic species single oxygen for relatively small quantities of AlSPc. Furthermore the toxic reactions is not dependent on cells being in an active phase of cycling, as demonstrated by the antibody targeted phototoxicity of unstimulated T-lymphocytes. This means that clonogenic cells in Go can be targeted and destroyed. The T-lymphocytes in this study were obtained from 'non-responders'. These are donors whose T-lymphocytes are not activated via the CD3 pathway in response to the binding of anti-CD3 antibodies, in this case of subclass IgGI (Smith et al., 1986) , thus ensuring that the lymphocytes were quiescent during treatment.
The use of a polyclonal antibody on the liposomes means that several mouse monoclonal antibodies can be used together as a cocktail with the same AlSPc preparation. Also, because the AlSPc containing liposomes need not be internalised to be toxic (Morgan et al., 1989) , since the singlet oxygen produced is able to diffuse towards the cell, many cell surface antigens that would not normally be internalised can be used to extend the number of potential binding sites on the target cells. A combination of antibodies against both endocytosing and non-endocytosing antigens might be the best option to use, to attack the cell from both the inside and the outside.
